Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP015K |
| Synonyms | |
| Therapy Description |
Peficitinib (ASP015K) is a JAK inhibitor with increased selectivity for JAK3 over JAK1 and JAK2 (PMID: 25704750). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP015K | Peficitinib|JNJ-54781532 | JAK Inhibitor (Pan) 9 | Peficitinib (ASP015K) is a JAK inhibitor with increased selectivity for JAK3 over JAK1 and JAK2 (PMID: 25704750). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 L875H | hematologic cancer | predicted - sensitive | ASP015K | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L875H demonstrated some sensitivity to treatment with ASP015K (peficitinib) in culture, but were not as sensitive as cells expressing other JAK3 activating mutations (PMID: 31976485). | 31976485 |
| JAK3 M511I | hematologic cancer | sensitive | ASP015K | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 M511I were sensitive to treatment with ASP015K (peficitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
| JAK3 L857Q | hematologic cancer | sensitive | ASP015K | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L857Q were sensitive to treatment with ASP015K (peficitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|